# Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

> **NCT06606093** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 348 (estimated)

## Conditions studied

- Type 2 Diabetic Nephropathy

## Interventions

- **DRUG:** DWP16001 Placebo
- **DRUG:** DWP16001 0.3mg

## Key facts

- **NCT ID:** NCT06606093
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-23
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-01-31
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06606093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06606093, "Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06606093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*